This inventor holds 1 USPTO granted patent and 2 published patent applications. Top assignee: Korea Research Institute of Chemical Technology. Active years: 2024.
Company Filing History:
Years Active: 2024
Title: Innovations of Jung Yoon Yang
Introduction
Jung Yoon Yang is a notable inventor based in Daejeon, South Korea. He has made significant contributions to the field of pharmaceuticals, particularly in the development of novel compounds for medical applications. His work focuses on addressing autophagy-related diseases, which are critical in the context of modern health challenges.
Latest Patents
Jung Yoon Yang holds a patent for an isoquinoline derivative, which includes a preparing method and a pharmaceutical composition aimed at preventing or treating autophagy-related diseases. This innovative compound is designed to regulate autophagy activity, offering potential therapeutic benefits for conditions such as neurodegenerative diseases, cancer, metabolic disorders, inflammatory diseases, and issues related to melanogenesis. The patent highlights the versatility of the isoquinoline derivative, suggesting its use in health functional food compositions and cosmetic formulations with whitening functions.
Career Highlights
Jung Yoon Yang is affiliated with the Korea Research Institute of Chemical Technology, where he engages in cutting-edge research and development. His work is characterized by a commitment to advancing pharmaceutical science and improving health outcomes through innovative solutions. His contributions have been recognized within the scientific community, underscoring his role as a leading inventor in his field.
Collaborations
Jung Yoon Yang collaborates with esteemed colleagues, including Myung-Ae Bae and Dae-Seop Shin. These partnerships enhance the research efforts at the Korea Research Institute of Chemical Technology, fostering an environment of innovation and discovery.
Conclusion
Jung Yoon Yang's work exemplifies the impact of innovative research in the pharmaceutical industry. His patented isoquinoline derivative represents a significant advancement in the treatment of autophagy-related diseases, showcasing the potential of scientific innovation to improve health and well-being.